Over the past two decades, positron emission tomography (PET) has provided valuable insights into the mechanisms of nigrostriatal degeneration in Parkinson's disease (PD). Furthermore, it allows the in vivo assessment of disease progression and the evaluation of treatment interventions. In this review, we shall discuss some of the issues and concerns that arise with the use of PET as a surrogate marker of disease progression in Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molbrainres.2004.09.028 | DOI Listing |
Publication Analysis
Top Keywords
parkinson's disease
12
disease progression
12
vivo assessment
8
assessment disease
8
positron emission
8
emission tomography
8
disease
5
disease vivo
4
progression positron
4
tomography decades
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!